• BREAKING NEWS Shelter in place lifted after prisoner captured

Group recommends against routine PSA screenings

May 21, 2012 3:14:33 PM PDT
A major change in recommendations for cancer screening in men has been announced.

The government's health watchdogs, the United States Preventive Services Task Force, say men of all ages do not need to have the blood test for prostate cancer.

The PSA screening, which is a blood test that measures a specific chemical, has been encouraged for men as a way to catch early prostate cancer. Last year, this health agency published a draft of these guidelines. After hearing public commentary, they stood by their recommendations - PSA screenings for men are not recommended on a routine basis.

Why the change in a practice that has been encouraged for years? They say the harms outweigh the benefits. While a few men may benefit, many more will be harmed.

The new guidelines are based on 2 major trials. They found that nearly 90 percent of men whose cancer is detected with PSA screening undergo treatment, be it surgery, radiation or hormone therapy.

Five in a thousand will die within a month of surgery. Anywhere from 10 to 70 will suffer serious side effects from treatment, such as loss of control of urinary or bowel function, or erectile dysfunction.

Dr. Otis Brawley of the American Cancer Society agrees that screening should not be for everyone

"What I hope we can do is drive screening back to doctor patient relationship out of this mass screening of men in malls, in health fairs," he said.

Critics say the studies are flawed and underestimate the benefits of screening. Many urologists and cancer specialists say that telling people not to get screened is dangerous.

The guideline isn't a mandate. The task force stresses that men who want a PSA test still can get one, but only after the doctor explains the uncertainties. That's in part because the panel found PSA testing hasn't been studied adequately in black men and those with prostate cancer in the family, who are at highest risk of the disease.

The Obama administration said Monday that Medicare will continue to pay for PSA screenings, a simple blood test. Other insurers tend to follow Medicare's lead.

"This is important information for the public and men to have, and they should talk with their doctors about the risks and benefits of prostate cancer screening and make the decision that's best for them," said Mark Weber, a spokesman for the Department of Health and Human Services.

The task force advice goes a step further than major health groups including the American Cancer Society, which has long urged that men decide the issue for themselves after being told of PSA's pros and cons. But it's not likely to end an annual ritual for many men 50 and older. After all, the same task force has long urged men over 75 to skip PSA screening, and research suggests almost half of them still get tested.

The controversy will end only with development of better tests - to finally tell which men's tumors really will threaten their lives, and who will die with prostate cancer rather than from it, said Dr. Virginia Moyer of the Baylor College of Medicine, who heads the task force.

"We have been told for decades to be terrified of cancer and that the only hope is early detection and treatment," she said. The reality: "You don't need to detect all cancers."

"We don't want this to be the answer," Moyer added. "We want to screen for the ones that are going to be aggressive, manage those early - and leave everyone else alone."

In an editorial published with the guideline in Annals of Internal Medicine, some urologists argue the panel underestimated PSA's value and overestimated its harms.

"What PSA screening offers the men is a substantial opportunity to avoid dying a particularly unpleasant death from prostate cancer," said editorial co-author Dr. William Catalona of Northwestern University, who pioneered the testing.

He spoke Monday from a meeting of the American Urological Association, where doctors debated the guideline's impact. The urology association advises that men be informed of the potential risks and benefits before screening.

But Dr. Brawley, the American Cancer Society's chief medical officer, welcomed the task force's recommendation. He hoped it would help deter mass screenings, where men are given free PSAs at shopping malls and sports arenas without being told of the controversy, screenings that Brawley calls big business when health centers profit from the follow-up care.

"The question is, are we actually curing anybody who needs to be cured right now?" Brawley asked.

Too much PSA, or prostate-specific antigen, in the blood only sometimes signals prostate cancer is brewing. It also can mean a benign enlarged prostate or an infection. Only a biopsy can tell. Most men will get prostate cancer if they live long enough. Some 240,000 U.S. men a year are diagnosed with it, most with slow-growing tumors that carry a very low risk of morphing into the kind that can kill.

To evaluate whether routine screening saves lives, the task force analyzed previous research, focusing in particular on two huge studies in the U.S. and Europe. The panel's conclusion:

-Without screening, about 5 in every 1,000 men die of prostate cancer over 10 years. The European study found PSA testing might prevent one of those deaths, while the U.S. study found no difference.

-Of every 1,000 men screened, two will have a heart attack or stroke from resulting cancer treatment, and 30 to 40 will experience treatment-caused impotence or incontinence.

-Of every 3,000 men screened, one will die from complications of surgery.

Both the U.S. and European studies have flaws, and task force critics argue over which are most believable. And while U.S. death rates from prostate cancer have dropped over 20 years, the cancer society's Brawley says the drop began before PSA testing became widespread. Moreover, the risk of death is the same in Europe and the U.S. even though many more American men are screened, diagnosed and treated, he said.

"We need to do a better job of using PSA wisely," said Dr. Scott Eggener, a University of Chicago prostate cancer specialist who was disappointed the task force went so far. "Most people would agree that a well-informed, young, healthy patient should have the opportunity to talk about it with their physician."

But he's studying a way beyond the screen-or-not controversy: Having men with small, low-risk tumors postpone treatment in favor of "active surveillance," keeping close watch on their tumors and treating only if they grow. More than 100,000 men a year are candidates, concluded a recent meeting at the National Institutes of Health.

That approach could "maximize the benefits of screening," Eggener said.

---
Information from The Associated Press is included in this report.

---
Online:

Task force information: http://www.uspreventiveservicestaskforce.org/recommendations.htm

Journal's patient summary: http://bit.ly/LbhSxH

---
Get Eyewitness News Delivered

Facebook | Twitter | Newsletters | Text Alerts


Load Comments